The std diagnostics market size has grown rapidly in recent years. It will grow from $10.77 billion in 2025 to $11.91 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing prevalence of sexually transmitted infections, expansion of diagnostic laboratory infrastructure, growing public health screening programs, rising awareness of sexual health, availability of advanced nucleic acid testing.
The std diagnostics market size is expected to see rapid growth in the next few years. It will grow to $17.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostics, rising adoption of home-based testing kits, expansion of molecular diagnostics penetration, growing investments in public health surveillance, increasing focus on confidential and accessible testing services. Major trends in the forecast period include increasing adoption of rapid and point-of-care std tests, rising use of molecular diagnostic technologies, growing integration of automated laboratory systems, expansion of at-home std testing solutions, enhanced focus on early and accurate disease detection.
The increasing incidence of sexually transmitted diseases is expected to drive the expansion of the STD diagnostics sector in the coming years. Sexually transmitted diseases are infections spread primarily through sexual contact and require timely medical testing and clinical management. The rising burden of these infections is largely attributed to higher levels of sexual activity and evolving social behaviors among younger populations, where reduced stigma around sexual health and increased mobility have contributed to broader sexual networks and elevated transmission risks. This growing prevalence directly fuels demand for diagnostic solutions, as healthcare providers increasingly rely on precise laboratory assays, screening tools, and advanced detection technologies to identify infections early and limit further spread. For example, in September 2025, data from the Centers for Disease Control and Prevention indicated that cases of congenital syphilis increased for the twelfth consecutive year, reaching nearly 4,000 reported cases in 2024. As a result, the rising prevalence of sexually transmitted diseases is contributing significantly to the growth of STD diagnostics.
Key companies in the STD diagnostics market are focusing on developing innovative products, such as real-time PCR kits, to meet unmet medical needs and improve diagnostic capabilities. A real-time PCR kit consists of a collection of reagents utilized for conducting real-time polymerase chain reaction (qPCR), a sensitive and commonly employed technique for detecting and quantifying specific nucleic acid sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based research and development company, introduced the Mycoplasma Hominis Real Time PCR Kit and the Treponema Pallidum Real Time PCR Kit, specifically designed for detecting Mycoplasma hominis and Treponema pallidum. These kits offer high sensitivity and specificity, user-friendliness, rapid turnaround times, and the capability to detect multiple pathogens in a single test.
In February 2024, Thyrocare, an India-based healthcare company, acquired Think Health Care for an undisclosed amount. With this acquisition, Thyrocare aims to strategically enhance its service offerings and market reach, especially in the home healthcare segment. Think Health Care is an India-based company specializing in diagnostic and preventive healthcare, known for providing at-home ECG services.
Major companies operating in the std diagnostics market are Abbott Laboratories, Qiagen Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Thermo Fisher Scientific Inc., Biocartis NV, Trinity Biotech PLC, Binx Health Inc., NOWDiagnostics Inc., Atlas Genetics Ltd., BioFire Diagnostics LLC, BioMérieux SA, Chembio Diagnostic Systems Inc., Corgenix Medical Corporation, Creative Diagnostics, Curetis AG, Daktari Diagnostics, Enzo Biochem Inc., Fujirebio Diagnostics Inc., GenePOC Inc., GenMark Diagnostics Inc., Grifols Diagnostic Solutions Inc., Hain Lifescience GmbH, Luminex Corporation, Meridian Bioscience Inc., Mesa Biotech Inc., Mobidiag Oy.
North America was the largest region in the STD diagnostics market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the std diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the std diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the std diagnostics market by increasing costs of imported reagents, assay kits, diagnostic instruments, and molecular testing components used in laboratory and point-of-care settings. Healthcare providers in North America and Europe are most affected due to reliance on imported test kits, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are raising testing prices and affecting screening program budgets. At the same time, they are supporting local reagent production, domestic diagnostic manufacturing, and regional supply chain strengthening.
The std diagnostics market research report is one of a series of new reports that provides std diagnostics market statistics, including std diagnostics industry global market size, regional shares, competitors with a std diagnostics market share, detailed std diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the std diagnostics industry. This std diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sexually Transmitted Diseases (STDs) diagnostics encompass the examination and identification of infectious conditions transmitted through sexual contact. These diagnostic procedures are essential in determining the presence of STDs within an individual.
The primary categories of STD diagnostics include chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus, human immunodeficiency virus, chancroid, and other tests performed in laboratory and point-of-care settings. Chlamydia testing involves a urine sample analysis to detect infection. This specific test is employed for identifying chlamydia infections, a common bacterial sexually transmitted infection (STI) transmitted through various forms of sexual contact or genital exposure. These STD diagnostic procedures find application in hospitals, clinics, diagnostic centers, and homecare settings.
The STD diagnostics market consists of revenues earned by entities by providing STD diagnostics tests such as cultural/isolated tests of organisms, molecular tests, and immunology assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The STD diagnostics market also includes sales of thermal cyclers, PCR, lateral flow readers - immuno chromatographic assays, flow cytometers, differential light scattering machines, absorbance microplate readers, phone chips, and rapid diagnostic kits which are used in providing STD diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The std diagnostics market size is expected to see rapid growth in the next few years. It will grow to $17.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostics, rising adoption of home-based testing kits, expansion of molecular diagnostics penetration, growing investments in public health surveillance, increasing focus on confidential and accessible testing services. Major trends in the forecast period include increasing adoption of rapid and point-of-care std tests, rising use of molecular diagnostic technologies, growing integration of automated laboratory systems, expansion of at-home std testing solutions, enhanced focus on early and accurate disease detection.
The increasing incidence of sexually transmitted diseases is expected to drive the expansion of the STD diagnostics sector in the coming years. Sexually transmitted diseases are infections spread primarily through sexual contact and require timely medical testing and clinical management. The rising burden of these infections is largely attributed to higher levels of sexual activity and evolving social behaviors among younger populations, where reduced stigma around sexual health and increased mobility have contributed to broader sexual networks and elevated transmission risks. This growing prevalence directly fuels demand for diagnostic solutions, as healthcare providers increasingly rely on precise laboratory assays, screening tools, and advanced detection technologies to identify infections early and limit further spread. For example, in September 2025, data from the Centers for Disease Control and Prevention indicated that cases of congenital syphilis increased for the twelfth consecutive year, reaching nearly 4,000 reported cases in 2024. As a result, the rising prevalence of sexually transmitted diseases is contributing significantly to the growth of STD diagnostics.
Key companies in the STD diagnostics market are focusing on developing innovative products, such as real-time PCR kits, to meet unmet medical needs and improve diagnostic capabilities. A real-time PCR kit consists of a collection of reagents utilized for conducting real-time polymerase chain reaction (qPCR), a sensitive and commonly employed technique for detecting and quantifying specific nucleic acid sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based research and development company, introduced the Mycoplasma Hominis Real Time PCR Kit and the Treponema Pallidum Real Time PCR Kit, specifically designed for detecting Mycoplasma hominis and Treponema pallidum. These kits offer high sensitivity and specificity, user-friendliness, rapid turnaround times, and the capability to detect multiple pathogens in a single test.
In February 2024, Thyrocare, an India-based healthcare company, acquired Think Health Care for an undisclosed amount. With this acquisition, Thyrocare aims to strategically enhance its service offerings and market reach, especially in the home healthcare segment. Think Health Care is an India-based company specializing in diagnostic and preventive healthcare, known for providing at-home ECG services.
Major companies operating in the std diagnostics market are Abbott Laboratories, Qiagen Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Thermo Fisher Scientific Inc., Biocartis NV, Trinity Biotech PLC, Binx Health Inc., NOWDiagnostics Inc., Atlas Genetics Ltd., BioFire Diagnostics LLC, BioMérieux SA, Chembio Diagnostic Systems Inc., Corgenix Medical Corporation, Creative Diagnostics, Curetis AG, Daktari Diagnostics, Enzo Biochem Inc., Fujirebio Diagnostics Inc., GenePOC Inc., GenMark Diagnostics Inc., Grifols Diagnostic Solutions Inc., Hain Lifescience GmbH, Luminex Corporation, Meridian Bioscience Inc., Mesa Biotech Inc., Mobidiag Oy.
North America was the largest region in the STD diagnostics market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the std diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the std diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the std diagnostics market by increasing costs of imported reagents, assay kits, diagnostic instruments, and molecular testing components used in laboratory and point-of-care settings. Healthcare providers in North America and Europe are most affected due to reliance on imported test kits, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are raising testing prices and affecting screening program budgets. At the same time, they are supporting local reagent production, domestic diagnostic manufacturing, and regional supply chain strengthening.
The std diagnostics market research report is one of a series of new reports that provides std diagnostics market statistics, including std diagnostics industry global market size, regional shares, competitors with a std diagnostics market share, detailed std diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the std diagnostics industry. This std diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sexually Transmitted Diseases (STDs) diagnostics encompass the examination and identification of infectious conditions transmitted through sexual contact. These diagnostic procedures are essential in determining the presence of STDs within an individual.
The primary categories of STD diagnostics include chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus, human immunodeficiency virus, chancroid, and other tests performed in laboratory and point-of-care settings. Chlamydia testing involves a urine sample analysis to detect infection. This specific test is employed for identifying chlamydia infections, a common bacterial sexually transmitted infection (STI) transmitted through various forms of sexual contact or genital exposure. These STD diagnostic procedures find application in hospitals, clinics, diagnostic centers, and homecare settings.
The STD diagnostics market consists of revenues earned by entities by providing STD diagnostics tests such as cultural/isolated tests of organisms, molecular tests, and immunology assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The STD diagnostics market also includes sales of thermal cyclers, PCR, lateral flow readers - immuno chromatographic assays, flow cytometers, differential light scattering machines, absorbance microplate readers, phone chips, and rapid diagnostic kits which are used in providing STD diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. STD Diagnostics Market Characteristics
3. STD Diagnostics Market Supply Chain Analysis
4. Global STD Diagnostics Market Trends and Strategies
5. STD Diagnostics Market Analysis of End Use Industries
7. Global STD Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global STD Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. STD Diagnostics Market Segmentation
10. STD Diagnostics Market Regional and Country Analysis
11. Asia-Pacific STD Diagnostics Market
12. China STD Diagnostics Market
13. India STD Diagnostics Market
14. Japan STD Diagnostics Market
15. Australia STD Diagnostics Market
16. Indonesia STD Diagnostics Market
17. South Korea STD Diagnostics Market
18. Taiwan STD Diagnostics Market
19. South East Asia STD Diagnostics Market
20. Western Europe STD Diagnostics Market
21. UK STD Diagnostics Market
22. Germany STD Diagnostics Market
23. France STD Diagnostics Market
24. Italy STD Diagnostics Market
25. Spain STD Diagnostics Market
26. Eastern Europe STD Diagnostics Market
27. Russia STD Diagnostics Market
28. North America STD Diagnostics Market
29. USA STD Diagnostics Market
30. Canada STD Diagnostics Market
31. South America STD Diagnostics Market
32. Brazil STD Diagnostics Market
33. Middle East STD Diagnostics Market
34. Africa STD Diagnostics Market
36. STD Diagnostics Market Competitive Landscape and Company Profiles
37. STD Diagnostics Market Other Major and Innovative Companies
40. STD Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
STD Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses std diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for std diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The std diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Chlamydia Testing; Syphilis Testing; Gonorrhea Testing; Herpes Simplex Virus Testing; Human Papilloma Virus Testing; Human Immunodeficiency Virus Testing; Chancroid Testing2) By Location Of Testing: Laboratory Testing; Point Of Care (PoC) Testing
3) By End-User: Hospitals And Clinics; Diagnostic Centers; Homecare
Subsegments:
1) By Chlamydia Testing: Nucleic Acid Amplification Tests (NAAT); Antigen Tests2) By Syphilis Testing: Rapid Plasma Reagin (RPR) Tests; Treponemal Tests
3) By Gonorrhea Testing: Nucleic Acid Amplification Tests (NAAT); Culture Tests
4) By Herpes Simplex Virus Testing: PCR Tests; Serological Tests
5) By Human Papilloma Virus Testing: HPV DNA Tests; HPV RNA Tests
6) By Human Immunodeficiency Virus Testing: Antibody Tests; Antigen Or Antibody Tests; Nucleic Acid Tests (NAT)
7) By Chancroid Testing: Culture Tests; Nucleic Acid Tests
Companies Mentioned: Abbott Laboratories; Qiagen Inc.; Danaher Corporation; F. Hoffmann-La Roche AG; Hologic Inc.; Bio-Rad Laboratories Inc.; Becton Dickinson and Company; Thermo Fisher Scientific Inc.; Biocartis NV; Trinity Biotech PLC; Binx Health Inc.; NOWDiagnostics Inc.; Atlas Genetics Ltd.; BioFire Diagnostics LLC; BioMérieux SA; Chembio Diagnostic Systems Inc.; Corgenix Medical Corporation; Creative Diagnostics; Curetis AG; Daktari Diagnostics; Enzo Biochem Inc.; Fujirebio Diagnostics Inc.; GenePOC Inc.; GenMark Diagnostics Inc.; Grifols Diagnostic Solutions Inc.; Hain Lifescience GmbH; Luminex Corporation; Meridian Bioscience Inc.; Mesa Biotech Inc.; Mobidiag Oy
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this STD Diagnostics market report include:- Abbott Laboratories
- Qiagen Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Hologic Inc.
- Bio-Rad Laboratories Inc.
- Becton Dickinson and Company
- Thermo Fisher Scientific Inc.
- Biocartis NV
- Trinity Biotech PLC
- Binx Health Inc.
- NOWDiagnostics Inc.
- Atlas Genetics Ltd.
- BioFire Diagnostics LLC
- BioMérieux SA
- Chembio Diagnostic Systems Inc.
- Corgenix Medical Corporation
- Creative Diagnostics
- Curetis AG
- Daktari Diagnostics
- Enzo Biochem Inc.
- Fujirebio Diagnostics Inc.
- GenePOC Inc.
- GenMark Diagnostics Inc.
- Grifols Diagnostic Solutions Inc.
- Hain Lifescience GmbH
- Luminex Corporation
- Meridian Bioscience Inc.
- Mesa Biotech Inc.
- Mobidiag Oy
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.91 Billion |
| Forecasted Market Value ( USD | $ 17.52 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
